UK-based CatSci have expanded their offering to now include cGMP analytical capabilities for both small molecule and oligonucleotides.
The new cGMP analytical capability will be led by Dr Sam Whitmarsh and Duncan Thompson, CatSci’s Director of Analytical Science and Digital Transformation, and Head of Dagenham site respectively.
Dr Nigel Richardson, CatSci’s Director of New Modalities, will lead the analytical development of oligonucleotides. QP Consultant Kate Smith will oversee all quality aspects.
The company’s analytical team will provide ICH Q14 aligned method development and validation, ICH Q3D elemental analysis, batch release, ICH stability testing, extractables and leachables, and oligonucleotides analytical development.
Dr Whitmarsh said: “After much hard work by our amazing team and a great partnership with Shimadzu, I am excited to launch this new chapter for analytical science at CatSci. The opening of our state-of-the-art GMP analytical facilities is not just a new space, it is a commitment to tackling key analytical challenges facing our customers, from method development and validation to oligonucleotides and trace analysis.”